MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Clinical trials for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New psoriasis drug shows promise in major trial
Disease control CompletedThis study tested a drug called bimekizumab in 435 adults with moderate to severe plaque psoriasis, a skin condition causing red, scaly patches. Participants received either bimekizumab or a placebo for 16 weeks to see if the drug could clear most of the skin symptoms. The goal w…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New psoriasis drug shows promise in chinese trial
Disease control CompletedThis study tested a drug called bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo for 16 weeks. The main goals were to see if the drug could clear at least 90% of psoriasis symptoms and improve skin appe…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Promising new psoriasis treatment shows major skin clearing in trial
Disease control CompletedThis study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see if bimekizumab could significantly clear skin symptoms by week 16. Results…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for kids with psoriasis: Real-World study shows cosentyx works
Disease control CompletedThis study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx (secukinumab) for up to 52 weeks. Researchers tracked side effects and how well the drug cleared skin symptoms. The goal was to see if Cosentyx is safe an…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Psoriasis drug shows promise in Long-Term safety trial
Disease control CompletedThis study looked at the long-term safety of bimekizumab in 1,353 adults with moderate to severe plaque psoriasis. Participants who completed earlier studies received open-label bimekizumab and were monitored for side effects over time. The goal was to see how safe and tolerable …
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New psoriasis drug matches up against stelara in head-to-head trial
Disease control CompletedThis study tested whether a new drug called Bmab 1200 works as well as the approved drug Stelara for people with moderate to severe plaque psoriasis. 384 adults took part and received either Bmab 1200 or Stelara. The main goal was to see how much their psoriasis improved after 12…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: Biocon Biologics UK Ltd • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New shot clears psoriasis in weeks: phase 3 trial shows promise
Disease control CompletedThis study tested a new medicine called JS005, given as a shot under the skin, for adults with moderate to severe plaque psoriasis. About 700 people took part. The goal was to see if JS005 could clear skin patches better than a placebo after 12 weeks. Results showed that more peo…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New psoriasis drug shows promise in Head-to-Head trial
Disease control CompletedThis study tested a new drug called bimekizumab against an existing drug, secukinumab, in 743 adults with moderate-to-severe plaque psoriasis. The main goal was to see which drug cleared more skin completely by week 16. Both drugs are given by injection and aim to control the dis…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC